Allelica powers PROACT 3 clinical trial with multi-ancestry polygenic risk score testing
· Apr 7, 2026
<p>SAN FRANCISCO, April 7, 2026 /PRNewswire/ -- Allelica, the global leader in multi-ancestry clinical polygenic risk score (PRS) testing, has been selected as the PRS testing collaborator for the PROACT 3 clinical trial at Mass General Brigham. Led by principal investigator Dr. Akl Fahed of...</p>
This article was originally published at www.prnewswire.com.